Teva Pharmaceutical Industries Ltd (TEVA) 51.33 $T
Post# of 273249
Posted On: 09/06/2016 11:03:53 PM
Teva Pharmaceutical Industries Ltd (TEVA) 51.33 $TEVA
Teva UK Study Reveals Generational 'Digital Divide' as UK Baby Boomers Fail to Embrace Benefits of 'Digital Healthcare'
PR Newswire Europe - Tue Sep 06, 6:02PM CDT
CASTLEFORD, England, September 7, 2016 /PRNewswire/ --
TEVA: 51.33 (+0.11)
Teva to Present at the Wells Fargo 2016 Healthcare Conference
BusinessWire - Tue Sep 06, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Wells Fargo Healthcare Conference. Eyal Desheh will present on Wednesday, September 7, 2016 at 1:10 PM ET.
TEVA: 51.33 (+0.11), WFC: 49.99 (-0.56)
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11)
InvestorsObserver releases covered-call reports for Chipotle Mexican Grill, Hewlett Packard Enterprise Company, Teva, VeriFone Systems and Wynn Resorts
PR Newswire - Fri Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HPE, PAY, TEVA, and WYNN.
CMG: 414.07 (+5.66), WYNN: 92.79 (+0.41), TEVA: 51.33 (+0.11), PAY: 16.82 (+0.01), HPE: 21.86 (-0.35)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 63.24 (+0.26), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), BMY: 56.96 (+0.61), NVS: 80.15 (+0.77)
Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International Congress
BusinessWire - Tue Aug 30, 6:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that five company-sponsored abstracts will be presented at the 2016 European Respiratory Society (ERS) International Congress in London, England on September 3-7, 2016.
TEVA: 51.33 (+0.11)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 239.12 (+3.16), GNRX: 24.86 (+0.46), PRGO: 92.07 (+1.32), AXGN: 8.94 (+0.05), AKRX: 26.46 (-0.01), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), AMPH: 18.91 (+0.35), NVS: 80.15 (+0.77)
Teva to Host Generic Medicines Business Overview on September 9, 2016
BusinessWire - Mon Aug 29, 10:50AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.m. ET to communicate an overview of the future prospects of Teva Generics business following the close of the Actavis generics deal. The presentation will focus on strategy, commercial, portfolio and R&D capabilities and will include an overview of specific pipeline opportunities in 2017 and beyond.
TEVA: 51.33 (+0.11)
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 31.52 (-0.27), BSTC: 36.10 (-0.46), MYL: 40.40 (+0.43), USNA: 138.69 (+0.53), TEVA: 51.33 (+0.11)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.52 (-0.27), ENDP: 20.49 (+0.67), VRX: 29.47 (+0.71), BSTC: 36.10 (-0.46), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), USNA: 138.69 (+0.53)
Novartis (NVS) Reports Positive Phase III Results on MS Drug
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:20AM CDT
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
TEVA: 51.33 (+0.11), CORT: 5.48 (+0.17), PCRX: 40.79 (+1.75), NVS: 80.15 (+0.77)
Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:29AM CDT
Mylan (MYL) announced that the U.S. Patent and Trademark Office has invalidated two of Teva Copaxone 40 mg patents in an inter partes review.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11)
Teva Confirms PTAB's Decisions on Two Patents in IPR Challenge to COPAXONE(R) 40 mg
BusinessWire - Wed Aug 24, 4:46PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the Patent Trial and Appeal Board (PTAB) decisions from an Inter Partes Review (IPR) to invalidate all claims of the '250 and '413 patents for 40 mg COPAXONE(R) (glatiramer acetate injection). Teva plans to appeal to the United States Court of Appeals for the Federal Circuit
TEVA: 51.33 (+0.11)
Teva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE® 40mg/mL by Health Canada
CNW Group - Tue Aug 23, 6:59AM CDT
Teva Canada Innovation, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved three-times-a-week COPAXONE® (glatiramer acetate) 40 mg/mL injection. This new formulation of COPAXONE® will allow for a less frequent dosing regimen for patients with relapsing remitting multiple sclerosis (RRMS). In addition to the newly approved dose, daily COPAXONE® 20 mg/mL will continue to be available.
TEVA: 51.33 (+0.11)
Pfizer's (PFE) Pain Drug Troxyca ER Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:45AM CDT
Pfizer (PFE) gained FDA approval for Troxyca ER with abuse-deterrent properties for the management of pain.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), PFE: 34.77 (unch), TEVA: 51.33 (+0.11)
Top Research Reports for August 19, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 19, 10:44AM CDT
Top Research Reports for August 19, 2016
ZTS: 51.29 (+0.03), AVB: 178.83 (+3.37), LOW: 76.01 (-0.95), TEVA: 51.33 (+0.11), CMCSA: 66.34 (+0.18), VZ: 53.51 (+0.63)
Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:23AM CDT
Teva Pharmaceutical's (TEVA) Cinqaero has gained approval in the EU for the treatment of adult patients with severe eosinophilic asthma.
AZN: 33.09 (-0.22), TEVA: 51.33 (+0.11), GSK: 43.99 (-0.27), ANIK: 48.34 (+0.45)
Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Arpita Dutt - Zacks Investment Research - Mon Aug 15, 8:13AM CDT
The deal will see Allergan (AGN) making an upfront payment of $95 million as well as a launch milestone payment related to ForSight's lead development program.
AGN: 239.12 (+3.16), BIIB: 310.67 (-2.92), TEVA: 51.33 (+0.11), NVS: 80.15 (+0.77)
Post Earnings Coverage as Allergan Tops Earnings Expectation Bolstered By Botox
ACCESSWIRE - Thu Aug 11, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 11, 2016 / Active Wall St. announces its post-earnings coverage on Allergan PLC (NYSE: AGN). The company reported second-quarter 2016 results before the opening bell on August 08th, 2016. The Irish pharmaceutical giant reported slight increase in revenue despite missing market expectations. Register with us now for your free membership at: http://www.activewallst.com/register/.
AGN: 239.12 (+3.16), PFE: 34.77 (unch), TEVA: 51.33 (+0.11)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 1.31% Sell Off
Comtex SmarTrend(R) - Wed Aug 10, 12:20PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $52.55 to a high of $53.48. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $52.93 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 51.33 (+0.11)
Teva UK Study Reveals Generational 'Digital Divide' as UK Baby Boomers Fail to Embrace Benefits of 'Digital Healthcare'
PR Newswire Europe - Tue Sep 06, 6:02PM CDT
CASTLEFORD, England, September 7, 2016 /PRNewswire/ --
TEVA: 51.33 (+0.11)
Teva to Present at the Wells Fargo 2016 Healthcare Conference
BusinessWire - Tue Sep 06, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Wells Fargo Healthcare Conference. Eyal Desheh will present on Wednesday, September 7, 2016 at 1:10 PM ET.
TEVA: 51.33 (+0.11), WFC: 49.99 (-0.56)
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11)
InvestorsObserver releases covered-call reports for Chipotle Mexican Grill, Hewlett Packard Enterprise Company, Teva, VeriFone Systems and Wynn Resorts
PR Newswire - Fri Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HPE, PAY, TEVA, and WYNN.
CMG: 414.07 (+5.66), WYNN: 92.79 (+0.41), TEVA: 51.33 (+0.11), PAY: 16.82 (+0.01), HPE: 21.86 (-0.35)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 63.24 (+0.26), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), BMY: 56.96 (+0.61), NVS: 80.15 (+0.77)
Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International Congress
BusinessWire - Tue Aug 30, 6:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that five company-sponsored abstracts will be presented at the 2016 European Respiratory Society (ERS) International Congress in London, England on September 3-7, 2016.
TEVA: 51.33 (+0.11)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 239.12 (+3.16), GNRX: 24.86 (+0.46), PRGO: 92.07 (+1.32), AXGN: 8.94 (+0.05), AKRX: 26.46 (-0.01), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), AMPH: 18.91 (+0.35), NVS: 80.15 (+0.77)
Teva to Host Generic Medicines Business Overview on September 9, 2016
BusinessWire - Mon Aug 29, 10:50AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.m. ET to communicate an overview of the future prospects of Teva Generics business following the close of the Actavis generics deal. The presentation will focus on strategy, commercial, portfolio and R&D capabilities and will include an overview of specific pipeline opportunities in 2017 and beyond.
TEVA: 51.33 (+0.11)
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 31.52 (-0.27), BSTC: 36.10 (-0.46), MYL: 40.40 (+0.43), USNA: 138.69 (+0.53), TEVA: 51.33 (+0.11)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.52 (-0.27), ENDP: 20.49 (+0.67), VRX: 29.47 (+0.71), BSTC: 36.10 (-0.46), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), USNA: 138.69 (+0.53)
Novartis (NVS) Reports Positive Phase III Results on MS Drug
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:20AM CDT
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
TEVA: 51.33 (+0.11), CORT: 5.48 (+0.17), PCRX: 40.79 (+1.75), NVS: 80.15 (+0.77)
Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:29AM CDT
Mylan (MYL) announced that the U.S. Patent and Trademark Office has invalidated two of Teva Copaxone 40 mg patents in an inter partes review.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11)
Teva Confirms PTAB's Decisions on Two Patents in IPR Challenge to COPAXONE(R) 40 mg
BusinessWire - Wed Aug 24, 4:46PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the Patent Trial and Appeal Board (PTAB) decisions from an Inter Partes Review (IPR) to invalidate all claims of the '250 and '413 patents for 40 mg COPAXONE(R) (glatiramer acetate injection). Teva plans to appeal to the United States Court of Appeals for the Federal Circuit
TEVA: 51.33 (+0.11)
Teva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE® 40mg/mL by Health Canada
CNW Group - Tue Aug 23, 6:59AM CDT
Teva Canada Innovation, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved three-times-a-week COPAXONE® (glatiramer acetate) 40 mg/mL injection. This new formulation of COPAXONE® will allow for a less frequent dosing regimen for patients with relapsing remitting multiple sclerosis (RRMS). In addition to the newly approved dose, daily COPAXONE® 20 mg/mL will continue to be available.
TEVA: 51.33 (+0.11)
Pfizer's (PFE) Pain Drug Troxyca ER Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:45AM CDT
Pfizer (PFE) gained FDA approval for Troxyca ER with abuse-deterrent properties for the management of pain.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), PFE: 34.77 (unch), TEVA: 51.33 (+0.11)
Top Research Reports for August 19, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 19, 10:44AM CDT
Top Research Reports for August 19, 2016
ZTS: 51.29 (+0.03), AVB: 178.83 (+3.37), LOW: 76.01 (-0.95), TEVA: 51.33 (+0.11), CMCSA: 66.34 (+0.18), VZ: 53.51 (+0.63)
Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:23AM CDT
Teva Pharmaceutical's (TEVA) Cinqaero has gained approval in the EU for the treatment of adult patients with severe eosinophilic asthma.
AZN: 33.09 (-0.22), TEVA: 51.33 (+0.11), GSK: 43.99 (-0.27), ANIK: 48.34 (+0.45)
Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Arpita Dutt - Zacks Investment Research - Mon Aug 15, 8:13AM CDT
The deal will see Allergan (AGN) making an upfront payment of $95 million as well as a launch milestone payment related to ForSight's lead development program.
AGN: 239.12 (+3.16), BIIB: 310.67 (-2.92), TEVA: 51.33 (+0.11), NVS: 80.15 (+0.77)
Post Earnings Coverage as Allergan Tops Earnings Expectation Bolstered By Botox
ACCESSWIRE - Thu Aug 11, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 11, 2016 / Active Wall St. announces its post-earnings coverage on Allergan PLC (NYSE: AGN). The company reported second-quarter 2016 results before the opening bell on August 08th, 2016. The Irish pharmaceutical giant reported slight increase in revenue despite missing market expectations. Register with us now for your free membership at: http://www.activewallst.com/register/.
AGN: 239.12 (+3.16), PFE: 34.77 (unch), TEVA: 51.33 (+0.11)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 1.31% Sell Off
Comtex SmarTrend(R) - Wed Aug 10, 12:20PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $52.55 to a high of $53.48. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $52.93 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 51.33 (+0.11)
(0)
(0)Scroll down for more posts ▼